Compound Details
CLOMINOVA tablets contain Clomiphene Citrate (CAS 50-41-9). Pharmaceutical-grade hormone support by NovaTech Sciences for fertility treatment, estrogen modulation, and reproductive health.
Form
Oral tablet
Strength
50 mg Clomiphene Citrate per tablet
Pack Size
10 tablets per box
Packaging
Secure, tamper-proof pharmaceutical-grade packaging
Usage
PCT, testosterone recovery, endocrine support, hormone balance post-steroid cycle
Storage
Store in a cool, dry place away from sunlight.
CLOMINOVA Tablets by NovaTech Sciences contain pharmaceutical-grade Clomiphene Citrate (CAS 50-41-9), a selective estrogen receptor modulator (SERM) widely used in reproductive medicine to support ovulation stimulation and hormonal balance. Clomiphene Citrate is globally identified through CAS 50-41-9, ensuring chemical authenticity, pharmaceutical traceability, and standardized quality across international healthcare markets.
NovaTech Sciences manufactures Clomiphene Citrate CAS 50-41-9 using strict pharmaceutical production standards designed to maintain compound purity, dosage consistency, and reliable global supply.
Clomiphene Citrate, registered under CAS 50-41-9, is a medication commonly used to treat infertility caused by ovulation disorders. It works by stimulating hormonal pathways that trigger ovulation in women who do not ovulate regularly.
The CAS registry number 50-41-9 serves as the globally recognized chemical identifier for Clomiphene Citrate. This identifier ensures accurate compound verification and regulatory transparency throughout pharmaceutical manufacturing and distribution systems.
Clomiphene Citrate has been widely studied in reproductive medicine and endocrinology for its ability to influence estrogen signaling pathways and stimulate ovarian function.
Clomiphene Citrate (CAS 50-41-9) works by interacting with estrogen receptors in the hypothalamus. By blocking estrogen's negative feedback effect, the medication signals the body to produce more reproductive hormones.
These hormones stimulate ovarian follicle development and promote ovulation. Through this mechanism, Clomiphene Citrate CAS 50-41-9 supports fertility treatment protocols designed to help individuals conceive.
Each production batch of Clomiphene Citrate CAS 50-41-9 undergoes strict laboratory testing to confirm compound purity, identity verification, and dosage stability.
NovaTech Sciences is a trusted manufacturer, supplier, and exporter of pharmaceutical-grade hormone therapy compounds for international healthcare markets. By clearly specifying CAS 50-41-9, CLOMINOVA tablets maintain chemical authenticity and regulatory compliance.
These processes ensure Clomiphene Citrate tablets meet strict pharmaceutical distribution standards.
NovaTech Sciences focuses on pharmaceutical precision, regulatory compliance, and reliable supply. CLOMINOVA tablets containing Clomiphene Citrate CAS 50-41-9 are manufactured using advanced pharmaceutical technologies designed to maintain consistent product quality.
For pharmaceutical distributors and healthcare suppliers seeking a reliable source of Clomiphene Citrate (CAS 50-41-9), CLOMINOVA Tablets by NovaTech Sciences provide verified compound identity, pharmaceutical manufacturing excellence, and dependable global supply. Supported by strict quality assurance protocols, Clomiphene Citrate CAS 50-41-9 remains a widely recognized medication associated with fertility support, hormone balance, and reproductive health therapies.
Precautions
Contraindications
Clomiphene Citrate, also written as Clomifene Citrate in UK medical references, is a selective oestrogen receptor modulator identified by CAS Number 50-41-9. Its molecular formula is C32H36ClNO8, with a molecular weight of approximately 598.08 g/mol. The compound is generally formulated as an oral prescription medicine and is associated with medically supervised fertility treatment.
This Nova Techsciences compound page should provide accurate chemical identification, balanced safety information and transparent regulatory context. It must not replace authorised prescribing information, a patient information leaflet or consultation with an appropriately qualified healthcare professional.
Clomiphene Citrate belongs to a group of medicines described as ovulation stimulants. In authorised UK prescribing information, it is used for certain types of infertility in women who do not ovulate properly. The medicine is classified as prescription-only and requires assessment of other possible fertility problems before treatment begins.
Clomiphene Citrate interacts with oestrogen receptors involved in hormonal feedback. Its effects on the hypothalamic-pituitary system can encourage the release of hormones associated with follicular development and ovulation.
Because fertility conditions have different underlying causes, the compound is not suitable for every patient. Professional assessment may include reproductive history, pregnancy testing and evaluation of ovarian, thyroid, adrenal, pituitary, uterine and male-factor conditions.
A dependable Clomiphene Citrate compound profile should be supported by documented pharmaceutical controls. These may include:
Every batch should have a traceable identification number connected to manufacturing and laboratory-release records. Claims concerning pharmaceutical grade, purity or international compliance should only be published when supported by current documentation.
For the United Kingdom, Netherlands and other European markets, Nova Techsciences should clearly disclose the applicable marketing-authorisation status, legal supply category, responsible organisation and adverse-event reporting procedure.
Important risks associated with Clomiphene Citrate include multiple pregnancy, ectopic pregnancy, ovarian enlargement, ovarian hyperstimulation and visual disturbances. Authorised UK information states that it should not be used during pregnancy or by people with certain liver conditions, unexplained menstrual bleeding, hormone-sensitive cancers or particular ovarian cysts.
Clomiphene Citrate should not be presented for unsupervised hormone management, bodybuilding or post-cycle use. Patients should not begin, change or discontinue treatment without professional medical guidance.
Testosterone Propionate is an esterified anabolic-androgenic hormone identified by CAS Number 57-85-2. It has different pharmaceutical properties, risks and regulatory requirements from Clomiphene Citrate and requires separate sterile-manufacturing documentation and professional hormonal monitoring.
A Testosterone Blend combines multiple testosterone esters within one formulation. Each ester and concentration should be identified separately in technical records because CAS Number 58-22-0 refers to the parent testosterone compound rather than the complete blended preparation.
Testosterone Cypionate is an esterified testosterone compound identified by CAS Number 58-20-8. Its product information should independently address prescription status, contraindications, cardiovascular and reproductive considerations, batch sterility and laboratory traceability.
Testosterone Enanthate is identified by CAS Number 315-37-7. It is chemically distinct from Clomiphene Citrate and requires separate information covering formulation strength, endocrine monitoring, adverse reactions, legal supply conditions and injectable-product quality controls.
Boldenone Undecylenate is an anabolic-androgenic steroid identified by CAS Number 13103-34-9. It should not be presented as interchangeable with fertility medicines and requires independent regulatory, cardiovascular, hormonal and reproductive safety information.
Clomiphene Citrate should ultimately be presented through correct CAS identification, evidence-based medical information, transparent batch documentation and clearly stated regulatory limitations.
Premium aromatase inhibitor tablets for estrogen suppression and effective hormone balance support.
Buy Tamoxifen Citrate (CAS 54965-24-1) by NovaTech Sciences. Premium tablets for estrogen modulation, hormone support, and targeted receptor activity.
Buy Anastrozole (CAS 120511-73-1) by NovaTech Sciences. Pharmaceutical-grade aromatase inhibitor tablets for estrogen suppression and hormone regulation.
